Literature DB >> 11549567

Glioma classification: a molecular reappraisal.

D N Louis1, E C Holland, J G Cairncross.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11549567      PMCID： PMC1850454          DOI： 10.1016/S0002-9440(10)61750-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  33 in total

1.  Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment.

Authors:  M Montesinos-Rongen; R Küppers; D Schlüter; T Spieker; D Van Roost; C Schaller; G Reifenberger; O D Wiestler; M Deckert-Schlüter
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas.

Authors:  A von Deimling; D N Louis; K von Ammon; I Petersen; O D Wiestler; B R Seizinger
Journal:  Cancer Res       Date:  1992-08-01       Impact factor: 12.701

3.  Successful chemotherapy for newly diagnosed aggressive oligodendroglioma.

Authors:  D R Macdonald; L E Gaspar; J G Cairncross
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

4.  The biology of astrocytoma: lessons learned from chronic myelogenous leukemia--hypothesis.

Authors:  J G Cairncross
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

5.  Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas.

Authors:  D T Ransom; S R Ritland; D W Kimmel; C A Moertel; R J Dahl; B W Scheithauer; P J Kelly; R B Jenkins
Journal:  Genes Chromosomes Cancer       Date:  1992-11       Impact factor: 5.006

6.  Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors.

Authors:  M J Bello; J Vaquero; J M de Campos; M E Kusak; J L Sarasa; J Saez-Castresana; A Pestana; J A Rey
Journal:  Int J Cancer       Date:  1994-04-15       Impact factor: 7.396

7.  Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.

Authors:  F F Lang; D C Miller; M Koslow; E W Newcomb
Journal:  J Neurosurg       Date:  1994-09       Impact factor: 5.115

8.  Comparative study of p53 gene and protein alterations in human astrocytic tumors.

Authors:  D N Louis; A von Deimling; R Y Chung; M P Rubio; J M Whaley; R H Eibl; H Ohgaki; O D Wiestler; A D Thor; B R Seizinger
Journal:  J Neuropathol Exp Neurol       Date:  1993-01       Impact factor: 3.685

9.  Subsets of glioblastoma multiforme defined by molecular genetic analysis.

Authors:  A von Deimling; K von Ammon; D Schoenfeld; O D Wiestler; B R Seizinger; D N Louis
Journal:  Brain Pathol       Date:  1993-01       Impact factor: 6.508

10.  Alterations of the TP53 gene in human gliomas.

Authors:  B K Rasheed; R E McLendon; J E Herndon; H S Friedman; A H Friedman; D D Bigner; S H Bigner
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701
View more
  70 in total

1.  Tumor growth, invasion, and angiogenesis in malignant gliomas.

Authors:  Eric T Wong
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

Review 2.  Molecular profiling in glioblastoma: prelude to personalized treatment.

Authors:  Nikol Mladkova; Arnab Chakravarti
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

3.  Molecular classification of brain tumor biopsies using solid-state magic angle spinning proton magnetic resonance spectroscopy and robust classifiers.

Authors:  Ovidiu C Andronesi; Konstantinos D Blekas; Dionyssios Mintzopoulos; Loukas Astrakas; Peter M Black; A Aria Tzika
Journal:  Int J Oncol       Date:  2008-11       Impact factor: 5.650

4.  Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours.

Authors:  Anna Batistatou; Panayiotis A Kyzas; Ann Goussia; Evdokia Arkoumani; Spyridon Voulgaris; Konstantinos Polyzoidis; Niki J Agnantis; Dimitrios Stefanou
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

5.  Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets.

Authors:  Dominique B Hoelzinger; Luigi Mariani; Joachim Weis; Tanja Woyke; Theresa J Berens; Wendy S McDonough; Andrew Sloan; Stephen W Coons; Michael E Berens
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

6.  Inducible expression of p57KIP2 inhibits glioma cell motility and invasion.

Authors:  K Sakai; A Peraud; T Mainprize; J Nakayama; A Tsugu; K Hongo; S Kobayashi; James T Rutka
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

7.  Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens.

Authors:  Sergio Comincini; Mayra Paolillo; Giulia Barbieri; Silvia Palumbo; Elena Sbalchiero; Alberto Azzalin; Marika A Russo; Sergio Schinelli
Journal:  J Biomed Biotechnol       Date:  2009-07-30

8.  Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets.

Authors:  Wolf Mueller; Christian Hartmann; Annegret Hoffmann; Wolfgang Lanksch; Jürgen Kiwit; Jörg Tonn; Julian Veelken; Johannes Schramm; Michael Weller; Otmar D Wiestler; David N Louis; Andreas von Deimling
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

9.  Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis.

Authors:  Filippo Calzolari; Irene Appolloni; Evelina Tutucci; Sara Caviglia; Marta Terrile; Giorgio Corte; Paolo Malatesta
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

10.  Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing.

Authors:  Fiona A Miller; Paul Krueger; Robert J Christensen; Catherine Ahern; Ronald F Carter; Suzanne Kamel-Reid
Journal:  BMC Health Serv Res       Date:  2009-07-30       Impact factor: 2.655
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.